Olema Pharmaceuticals, Inc.’s OLMA share price has dipped by 5.78%, which has investors questioning if this is right time to ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Major scientific discoveries can arise from simple decisions: say, by simply looking where virtually no one else has. Such ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

Nerve or neuropathic pain has long been a tricky condition to treat effectively. However, a new study has comprehensively ...

Relay Therapeutics, Inc.’s RLAY share price has surged by 5.63%, which has investors questioning if this is right time to sell.

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...

Multiple pharmaceutical agents in clinical trials promise to offer patients eye drops for the management of presbyopia.

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...

Getting therapeutic drugs past the blood-brain barrier has long been one of medicine's most difficult challenges, limiting ...